Appendix 4E and Financial Report for year ended 30 June 2019
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
Invion Limited
ACN 76 094 730 417
Appendix 4E – Final Report
Financial year ended
30 June 2019
Results for announcement to the market
Current Reporting Period:
30 June 2019
Previous Reporting Period:
30 June 2018
Revenue and Net Profit
Up/Down from
prior year
Revenue from continuing operations
Total income
Loss from ordinary activities after tax
Net Loss for the period
Up
Up
Increased
Decreased
Change from
prior year
%
426%
333%
175%
(78)%
Change from
prior year
$
3,144,383
2,963,674
1,619,698
(3,806,035)
Brief explanation of income and profit (loss)
The net loss attributable to the owners of the Company for the period ended 30 June 2019 was
$(1,064,098) (2018: $4,870,133 loss). Included in the loss was a $1,482,107 gain from discontinued
operations following the spin-out of the Group’s respiratory assets on 12 February 2019.
Performance and Shareholder Wealth
Earnings/(Loss) Per Share
Net tangible assets per share
Dividend per share
Share Price
2017
(0.14)
0.00
$0.003
2018
(0.13)
0.00
$0.04
2019
(0.02)
0.00
$0.02
Audit Report
This Appendix 4E (Final Report) is based on the audited financial statements for the year ended 30 June
2019, which are attached.
Invion Limited ABN 76 094 730 417
722 High Street, East Kew, VIC 3102 Australia
P: +61 3 9081 6005 W: www.inviongroup.com
Invion Limited
Financial report
For the year ended 30 June 2019
Contents
Directors’ Report
3
Consolidated statement of comprehensive income
15
Consolidated statement of financial position
16
Consolidated statement of changes in equity
17
Consolidated statement of cash flows
18
Notes to the financial statements
19
Directors’ declaration
41
Independent auditor’s report
42
Auditor’s independence declaration
47
Shareholder information
48
Corporate directory
51
2|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
DIRECTORS’ REPORT
Your Directors present their report of the Invion Group for the financial year ended 30 June 2019. The Invion Group
(“Group”) consists of Invion Limited (“Invion” or the “Company”) and its wholly owned subsidiary, IVX Cosmetics Pty
Ltd. The names and details of the Company’s Directors in office during the financial year and until the date of this report
are detailed below. Directors were in office for the entire period unless noted otherwise.
Thian Chew
Greg Collier PhD
James Campbell PhD
Alan Yamashita
Mitchell Glass MD
Chairman
Managing Director & CEO
Non-executive Director
Non-executive Director (appointed 12 February 2019)
Executive VP R&D and Chief Medical Officer (retired 12 February 2019)
Mr Thian Chew, Chairman
Appointed Non-executive Director and Chairman, 1 December 2017
Mr Chew has over 25 years’ experience in investing, finance and transforming business operations. He is Managing
Partner at Polar Ventures, a private investment and consulting firm that provides capital, strategic and operating
solutions, focusing on small to mid-sized enterprises in Asia. Mr Chew was previously an Executive Director at Goldman
Sachs (Hong Kong and New York) responsible for the firm’s proprietary investments including growth capital, private
equity and special situations in both private and public companies. Prior to this, he was a Consultant Project Manager
to Morgan Stanley, New York. Mr Chew also held a number of positions in KPMG across Asia Pacific including Director
at KPMG Consulting (Singapore and Sydney) where he led several large scale operational restructuring, post-merger
integration, transformation, and business performance improvement programs. As a Senior Manager at KPMG (Taipei
and Melbourne), he led several business process re-engineering initiatives, and also performed financial and
information technology audit, risk and assurance engagements across multiple industries. Mr Chew holds an MBA from
the Wharton School (Palmer Scholar), MA from the Lauder Institute, University of Pennsylvania, and a Bachelor of
Information Systems from Monash University. Mr Chew is an Adjunct Professor at HKUST’s MBA program and
previously qualified as a chartered accountant.
Greg Collier PhD, Managing Director & CEO
Appointed Managing Director and CEO, 6 May 2013
Dr Collier has more than 25 years experience spanning operational, clinical and scientific aspects of pharmaceutical
research, development and commercialisation. He has led the planning and execution of multiple commercial
transactions including in and out licensing deals and major M&A activities, and he has successfully taken a drug from
discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals from a researchbased company with a market capitalisation of $10m to a company with completed clinical trials and regulatory dossiers
submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon for $230m. Prior to his commercial
pharmaceutical career, Dr Collier had an outstanding academic career resulting in over 150 peer reviewed publications,
and senior authorship on 33 patents. Dr Collier was the inaugural Alfred Deakin Professor at Deakin University, and
also held positions at Melbourne University, Monash University and the University of Toronto. In 2010, Dr Collier was
awarded the Roche Award of Excellence for his contribution to the biotechnology industry. During the previous three
years, Dr Collier has also served as a director of Gemini Biotechnology, Prevatex, Barwon Biotechnology, Fusion
Biosciences Pty Ltd and Phosphagenics Limited (ASX:POH).
James Campbell PhD MBA, Non-executive Director
Appointed Non-executive Director, 26 February 2012
Dr James Campbell is a senior biotechnology executive with more than 25 years international experience in scientific
research, research management, management consulting and venture capital. Dr Campbell has held research
positions at the CNRS and the CSIRO. He is a principal of Gemini Biotechnology, a specialist biotechnology advisory
services company advising life science companies on M&A, partnering and corporate strategy. Dr Campbell was an
executive at ChemGenex Pharmaceuticals for nine years until the company was acquired in 2011, and has served on
the investment committee of UniSeed, a $60 million pre-seed venture fund, and various state and local government
advisory committees concerning biotechnology. During the previous three years, Dr Campbell has also served as a
director of Medibio Limited (ASX:MEB), Gemini Biotechnology, Fusion Biosciences Pty Ltd and Vitality Devices. Dr
Campbell is currently a non-executive director of Prescient Therapeutics Limited (ASX:PTX) and is the CEO/MD of
Patrys Limited (ASX:PAB).
3|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
Alan Yamashita, Non-executive Director
Appointed Non-executive Director, 12 February 2019
Mr Yamashita is a highly experienced corporate consultant and investment professional, with over 40 years' experience
in investment management, investment banking and alternative investment throughout the APAC region. From 1999
to 2005, Mr Yamashita was President and CEO of Search Investment Group and founding CEO and CIO of Search
Alternative Investment Ltd (SAIL), a major private global hedge fund and private equity investment practice
headquartered in Asia. Prior to Search Investments Group, Mr Yamashita was Managing Director and Head of Asia
Capital Markets for Merrill Lynch from 1996 to 1998. Mr Yamashita is currently Managing Partner at Polar Ventures
and has held numerous positions as a 16-year veteran of Goldman Sachs and an advisor to various companies,
including Plantation Timber Partners, Wuhan; Duty Free Shoppers, Asia; TVSN, Shanghai; and Mizuho Alternative
Investments LLC.
Mitchell Glass M.D., Executive Vice President R&D and Chief Medical Officer
Retired 12 February 2019
Dr Mitchell Glass is a 27 year veteran of the pharmaceutical industry. His experience is broad: - ranging from senior
positions in top ten pharmaceutical companies, to investment in and management of start-ups and biotechs. After seven
years of research, teaching and patient care at the University of Pennsylvania, Dr Glass joined ICI Pharmaceuticals in
1988 where he established the pulmonary therapeutics group and led the development and submission of the
antileukotriene ACCOLATE®. From 1995-6, Dr Glass was Vice President and Director at SmithKline Beecham where
he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialisation,
including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr Glass was Chief Medical Officer and VP
of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from
IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr Glass joined AQUMEN
Biopharmaceuticals KK and NA as CEO of AQUMEN NA and a Main Board Director. Since 2008, Dr Glass has been
a Director of OrphageniX Inc. (gene editing) and AVATAR Biotechnologies (biosimilars) and a consultant in R&D and
fundraising to early stage therapeutics companies. Dr Glass graduated from the University of Chicago and is board
certified in internal medicine, pulmonary and critical care medicine.
DIRECTORS’ INTERESTS IN INVION SECURITIES
In accordance with section 300(11) of the Corporations Act 2001, the interests of the Directors in the shares and options
of Invion Limited, as at the date of this report were:
Chew, Thian
Shares
548,497,721
Options
27,257,615
Collier, Greg
31,770,932
136,288,073
Campbell, James
4,186,772
20,443,211
Yamashita, Alan
-
20,443,211
584,455,425
204,432,110
DIRECTORS’ MEETINGS
The number of meetings of Directors and committees of Directors held in the year to 30 June 2019, and the number of
meetings attended by each Director, is as follows:
Board of
Directors
Eligible to
attend
Attended
Audit and Risk
Management Committee
Nomination and
Remuneration Committee
Eligible to
attend
Eligible to
attend
Attended
Attended
T Chew
8
8
2
2
-
-
G Collier
8
8
-
-
-
-
J Campbell
8
8
2
2
-
-
A Yamashita
3
3
-
-
-
-
M Glass
6
6
-
-
-
-
4|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
COMMITTEE MEMBERSHIP
At the date of this report the Company has the following Committees of the Board in place:
-
Audit and Risk Management Committee, the members of which are independent Non-executive Director Dr
James Campbell (chair) and non-independent Non-executive Director Mr Thian Chew.
-
Nomination and Remuneration Committee, the members of which are independent Non-executive Director
Dr James Campbell (chair) and non-independent Non-executive Director, Mr Thian Chew.
PRINCIPAL ACTIVITIES OF THE COMPANY IN THE YEAR UNDER REVIEW
The Invion Group consists of Invion Limited and, at 30 June 2019, its wholly owned subsidiary, IVX Cosmetics Pty Ltd.
The activity of Invion during the period was directed to the development of the PhotosoftTM technology for the treatment
of a range of cancers. Invion has been appointed exclusive licensee in Australia and New Zealand of Photosoft™. The
appointment has been made by technology licensor, The Cho Group, a Hong Kong based group that has funded and
successfully commercialised a number of unique and advanced technologies. Via an R&D services agreement between
the two entities, the development of Photosoft™ is funded by The Cho Group.
CORPORATE STRUCTURE
Invion Limited is an entity incorporated and domiciled in Australia. Invion’s shares have been publicly traded on the
Australian Securities Exchange since its listing on 15 February 2011 (ASX:IVX). At 30 June 2019, the Group had four
employees (3.5 FTE) (2018: 2 FTE).
FINANCIAL RESULTS AND DIVIDENDS
The loss after tax of the Group for continuing operations for the year ended 30 June 2019 was $2,546,205 (restated
2018: $926,507 loss). Included in the loss was $309,568 of depreciation and amortisation (restated 2018: $160,000)
and share based payment expense of $1,350,168 (2018: $15,174). No dividend was recommended or paid.
SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
Total equity is recorded at the Balance Date at $5,457,265 (2018: $7,906,345) a decrease of $2,449,080. The
movement is largely due to the reduction in cash on hand of $2,120,058 for the year.
On 16 November 2018, 19,700,000 unlisted share options on issue to employees and consultants to the Company,
lapsed, unexercised.
On 12 February 2019, following Shareholder approval at the Company’s General Meeting held 30 January 2019, the
Company issued 8,333,333 fully paid ordinary shares for the short-term incentive bonus to MD/CEO to be paid in equity.
Also on 12 February 2019, following Shareholder approval the Company issued 208,520,753 unlisted share options to
directors of the Company, and 140,831,010 unlisted share options to employees and consultants of the Company.
Options have an exercise price of $0.03 per Option (a 66% premium to market price of shares) and an expiry date of
12 February 2023. 20% of Options vested immediately upon issue, with the remaining options vesting in equal portions
over three years commencing 1 December 2019.
At the date of this report there were 351,059,116 (2018: 21,407,353) unissued ordinary shares under options. During
the year ended 30 June 2019, no ordinary shares of Invion Limited were issued upon the exercise of share options
granted (2018: 40,750,000).
The total issued securities of the Company are as follows:
At 30 June 2019
At the date of this Report
Ordinary shares
5,500,606,300
5,500,606,300
Share Options
351,059,116
351,059,116
5|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
REVIEW OF OPERATIONS
Invion is developing PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses nontoxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills
malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in
contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation,
expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion retains the commercialisation and distribution rights to Photosoft™ in Australia and New Zealand. The
development of Photosoft™ is funded via an R&D agreement with The Cho Group, which sees The Cho Group
providing non-dilutive funding to the company covering all development costs to meet pre-agreed development
milestones.
RESEARCH, FORMULATION AND DEVELOPMENT OF THE PHOTOSOFTTM TECHNOLOGY
On 5 July 2018, the Company announced that the initial characterisation of its in-licenced PhotosoftTM technology asset
had been completed in ovarian cancer under Invion’s Research & Development Alliance with Hudson Institute of
Medical Research. The studies showed that the PhotosoftTM technology caused efficient and highly effective cancer
cell destruction in vitro.
On 10 September 2018, the Company announced that PhotosoftTM had received patent protection in the area of cancer
treatment until 2033. On 25 September 2018, the Company announced new in vitro data that showed IVX-P02, an
improved formulation of PhotosoftTM, was 15 times more effective than PhotosoftTM at killing ovarian cancer cells.
On 7 November 2018, Invion announced partnerships with Formulytica and vivoPharm to formulate and test a gel
version of IVX-P02 as a photodynamic therapy (PDT) gel targeted to treat skin cancers.
On 16 January 2019, the Company announced the appointments of three new members to the Company’s Scientific
Advisory Board (SAB), which is expected to advance plans for clinical trials.
On 30 January 2019, at its General Meeting, Shareholders approved the appointment of Mr Alan Yamashita as a NonExecutive Director. At the General Meeting, Shareholders also approved the issue of 208,520,753 Share Options to
Directors and $150,000 worth of Invion Shares to the Managing Director and CEO. The issue of Invion Shares to the
Managing Director and CEO occurred on 12 February 2019. Each share was issued at the market price of $0.018
resulting in 8,333,333 shares issued. The issue of Share Options to Directors occurred on 12 February 2019. In
addition, 154,459,817 Share Options were issued to employees and consultants to the Company. Share Options issued
each have an exercise price of $0.03, an expiry date of 12 February 2023.
On 28 May 2019, the Company announced that its research partner, the Hudson Institute of Medical Research, had
completed initial in vivo experiments in animal models to examine the uptake, localisation and clearance from tumour
tissue of Invion’s photosensitiser, IVX-P02. Dr Andrew Stephens, Group Head of the Ovarian Cancer Biomarkers
Research Group at the Hudson Institute, said a highlight of the in vivo testing was the demonstrated uptake of IVX-P02
in circulating tumour cells (CTCs). CTCs are cells that have shed from a primary tumour and are carried around the
body in the blood. Dr Stephens said the finding was significant because it suggested that IVX-P02 may have an
application in the treatment of metastatic cancer, that is, cancer that has spread from the primary site of origin to
different areas of the body.
The in vivo data also showed that injected IVX-P02 cleared rapidly from circulation, with around 90% gone within 30
minutes and largely undetectable after two hours. Increasing doses up to 10mg/kg had no influence on the clearance
rate. The IVX-P02 accumulated in tumour tissue within 30 minutes of injection and was retained within tumour tissue
for at least 48 hours after administration. As anticipated from the in vitro studies, there was no toxicity noted for any
dose of IVX-P02 tested. Furthermore, there was no identification of any evidence of retention in any other organs,
including the liver, kidney, spleen, ovaries, fallopian tube, lung, heart, brain or intestine.
SPIN-OUT OF RESPIRATORY ASSETS
On 5 September 2018, the Company announced it intended to spin-off its two respiratory assets, Nadolol and
Zafirlukast, into a new public unlisted company, Chronic Airway Therapeutics Limited (CAT), which would develop the
products initially in China, with plans to advance towards Phase III clinical trials for Nadolol in 2019.
At the General Meeting held on 30 January 2019, Shareholders approved all resolutions relating to the Company’s
spin-out of respiratory assets. The record date for the spin-out transaction was 4 February 2019, and the spin-out
transaction completed on 12 February 2019, at which point each eligible Shareholder in Invion held one share in CAT
for each eligible share they held in Invion. The completion of the transaction did not alter the issued capital of Invion.
Upon completion of the spin-out, Dr Mitchell Glass retired from the Board of Directors to focus on the continued
development of the respiratory assets in CAT, where he is appointed Executive Director.
6|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
FORWARD STRATEGY AND OPERATIONAL TARGETS
Invion is developing the PhotosoftTM technology as an improved next generation Photodynamic Therapy. PDT uses
non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills
malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in
contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation,
expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.
Invion will conduct clinical development of Photosoft™ globally. The opportunities for treatment of skin cancer and
other topical applications, as well as intravenous treatment of lung, ovarian and prostate cancer are being explored.
Through its R&D services agreement with Invion, The Cho Group will provide non-dilutive funding for the clinical trials.
The clinical development program is being designed and managed by a joint steering committee between the two
companies.
LIKELY DEVELOPMENTS AND EXPECTED RESULTS
The likely developments in the operations of the Group and the expected results from those operations in future
financial years will be affected by the success of management in reaching critical development and commercial
milestones in its core program if the development of the PhotosoftTM technology. This will include developing and
expanding existing and emerging commercial partnerships with leading global healthcare companies, securing one or
more commercial transactions for the Group’s drug asset under development.
REGULATORY AND ENVIRONMENTAL MATTERS
Invion is required to carry out its activities in accordance with applicable environment and human safety regulations in
each of the jurisdictions in which it undertakes its operations. The Company is not aware of any matter that requires
disclosure with respect to any significant regulations in respect of its operating activities, and there have been no issues
of non-compliance during the year.
SIGNIFICANT EVENTS AFTER THE BALANCE DATE
On 22 July 2019, the Company announced that Chief Operating Officer, Craig Newton would transition to the role of
Chief Executive Officer effective 1 November 2019. Craig joined Invion as Chief Operating Officer in April 2018, and
since that time has recruited a strong and experienced clinical development team. Craig has over 30 years of
experience in senior business and operational roles gained at various leading global companies including CSL, Serono
UK, Bio Nova International, AVAX Australia and Cryptome Pharmaceuticals. The Company reported that Dr Greg
Collier is set to retire as MD and CEO, effective 31 October 2019, and that Dr Collier would remain on the Board as a
Non-Executive Director.
REMUNERATION REPORT (AUDITED)
This remuneration report for the year ended 30 June 2019 outlines the remuneration arrangements of the Group in
accordance with the requirements of the Corporations Act 2001 and its regulations. This information has been audited
as required by section 308(3C) of the Corporations Act 2001.
The remuneration report details the remuneration arrangements for key management personnel (KMP) who are defined
as those persons having authority and responsibility for planning, directing and controlling the major activities of the
Company, directly or indirectly, including any director, whether executive or otherwise.
For the purposes of this report, the term “Director” refers to non-executive directors (NEDs) only. “KMP” refers to
executive directors and other key management personnel.
The names and details of the Directors and KMP of the Group in office during the financial year and until the date of
this report are detailed below. Unless otherwise noted, Directors and KMP listed are in office at the date of the report.
There were no changes to KMP after 30 June 2019 and before the date this financial report was authorised for issue.
(i)
Non-executive Directors
Thian Chew
Chair
James Campbell PhD
Director
Alan Yamashita
Director (appointed 12 February 2019)
7|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
(ii)
(iii)
Executive Directors
Greg Collier PhD
Managing Director & CEO
Dr Mitchell Glass
EVP R&D and Chief Medical Officer (retired 12 February 2019)
Other key management personnel
Craig Newton
Chief Operating Officer
Melanie Farris
Chief Financial Officer and Company Secretary
Remuneration practice and philosophy
The Group’s guiding principle for remuneration is that remuneration should be simple and transparent, should reward
achievement, and should facilitate the alignment of shareholder and executive interests. The Company’s philosophy
is that shareholder and executive interests are best aligned:
•
•
•
by providing levels of fixed remuneration and ‘at risk’ pay sufficient to attract and retain individuals with the skills
and experience required to build on and execute the Company’s business strategy;
by ensuring ‘at risk’ remuneration is contingent on outcomes that grow and/or protect shareholder value; and,
by ensuring a suitable proportion of remuneration is received as a share-based payment.
Policy and process for remuneration setting and review
The Group aims to reward personnel with a level and mix of remuneration commensurate with their position and
responsibilities so as to:
•
•
•
•
attract and retain appropriately capable and talented individuals to the company;
reward personnel for corporate and individual performance;
align the interest of personnel with those of shareholders; and
build a strong cohesive leadership team which can deliver execution excellence against the strategy.
Remuneration consists of:
•
•
total fixed remuneration: base salary and superannuation; and
‘at risk’ remuneration: short-term incentives (STI) and long-term incentives (LTI).
There are no automatic adjustments to individual total fixed remuneration other than those required by law. Position
descriptions are prepared for all positions. Position descriptions are reviewed when necessary due to internal or
external changes and are considered as part of the annual performance and remuneration review. The Nomination and
Remuneration Committee recommends to the Board the remuneration packages for KMPs. The Committee may seek
external advice to determine the appropriate level and structure of the remuneration packages. The CEO determines
remuneration packages for non-KMP team members.
Total fixed remuneration
To ensure that the Company continues to attract, retain and motivate talented staff at a competitive cost, the Company
will aim to align total fixed remuneration to the median rate paid by others operating in the relevant market, with
consideration given to experience, qualifications, performance and other non-financial benefits. Total fixed
remuneration will be reviewed using market data to determine what, if any, adjustments may need to be made to
individual remuneration.
‘At risk’ remuneration
‘At risk’ remuneration elements are paid/issued following the performance and remuneration review conducted by
executive management; assessment by the Nomination and Remuneration Committee; and approval by the Board.
Short-term incentives (STI): cash bonus
STIs comprise up to 30% of fixed remuneration for the CEO and between 10% and 25% for other personnel. To provide
a framework for the assessment of performance and remuneration, each year, Key Performance Indicators (KPIs) will
be determined on a corporate and individual basis, based on the Board approved annual operational plan. Corporate
KPIs will be approved by the Board, and individual KPIs and commercial targets will be set by the CEO. STI calculations
and actual payment are based on achievement of KPIs.
Long-term incentives (LTI): equity grants
LTIs are offered to incentivise, reward and retain personnel, and to align the interests of personnel and shareholders.
The Nomination and Remuneration Committee considers the recommendation of the CEO regarding the issue of LTIs
8|I n v i o n L i m i t e d
Financial Report for the year ended 30 June 2019
Directors’ Report
in light of the performance, financial position and current issued capital of the company. There will be no automatic
grant of LTIs. At the discretion of the Board, the Company may also offer grants of LTIs as an award to incentivise
high-quality prospective employees to join the company.
The terms of any LTI grant are determined by the Board. LTI grants normally take the form of the issue of unlisted
share options. Share options are normally issued under the company’s equity incentive plan (EIP). All grants of equity
are determined by the Board.
Prior to 31 December 2018, the Board reviewed the general terms of new options to be issued. Options will be typically
granted with an exercise price that is between a 40-60% premium to the market price of shares on the day of issue,
and with an expiry date that is between three and four years from the date of issue. As LTIs are offered to incentivise,
reward and retain personnel, options will typically vest over a number of years.
The terms of the options, and what happens to options in the event of cessation of employment, are at the discretion
of the Board. However generally, in the event that a holder of unvested options ceases to be employed, then at the
absolute discretion of the Board, if the ceasing of employment is due to death or permanent disability, or in any other
circumstances determined by the Board to be on a “good leaver” basis, the next tranche of unvested options vests and
becomes exercisable for 30 days after the last day of engagement, after which those options expire. If at the absolute
discretion of the Board, the ceasing of employment occurs for any other reason than in “good leaver” circumstances,
including, but not limited to, termination for cause, or due to resignation, all unvested options lapse immediately and
the expiry date is taken to have occurred on the last day of engagement. In the event of a change of control, the Board,
at its absolute discretion, may determine that a proportion or all unvested awards will vest.
Nomination and Remuneration Committee
The objective of the Nomination and Remuneration Committee is to assist the Board in fulfilling its duties and
responsibilities by reviewing, advising and making recommendations to the Board on:
(a)
Nomination
•
•
•
•
(b)
Board composition and succession planning, taking into account diversity objectives and the mix of Director
skills and experience;
induction and continuing education for Directors;
Board performance evaluation; and
the performance of the CEO and key management personnel
Remuneration
•
•
•
•
implemen
Share your feedback
Discover